Source file,Variable name,Description,Variable type,Example,Categories ,Preprocessing needed,Expected missing rate,notes
detailed_descriptions.txt,description,A single text column that provides a detailed description of the study protocol.,text ,CD4-specific CAR is a chimeric antigen receptor immunotherapy treatment designed to treat lymphoma/leukemia expressing CD4 antigen. CD4+ T cell lymphomas are a subset of leukemias and lymphomas that are positive for the surface protein CD4. The purpose of this study is to evaluate the efficacy and safety of CD4 CAR T cells.,,,,Some terminated trials embed their stop reasons in the detailed description. This field may contain post-trial information and requires manual screening before inclusion in the LLM input.
brief_summaries.txt,description,A single text column that provides a brief description of the study.,text ,"This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD4 CAR T cells in patients with relapsed and/or refractory T cell lymphoma.",,,,
designs.txt,allocation,,categorical,,"NON_RANDOMIZED
RANDOMIZED ",No,,
designs.txt,intervention_model,,categorical,,"CROSSOVER    
FACTORIAL     
PARALLEL   
SEQUENTIAL
SINGLE_GROUP ",No,,
designs.txt,masking,,categorical,,"DOUBLE      
NONE 
QUADRUPLE    
SINGLE    
TRIPLE ",No,,"Detailed masking information is available for four roles (subject, caregiver, investigator, outcomes assessor). These may be useful features, and we may consider including them in the LLM input."
calculated_values.txt,number_of_primary_outcomes_to_measure,,numeric,,,No,,
calculated_values.txt,number_of_secondary_outcomes_to_measure,,numeric,,,No,,
calculated_values.txt,number_of_other_outcomes_to_measure,,numeric,,,No,,
eligibilities.txt,gender,,categorical,,"ALL 
FEMALE   
MALE ",No,,
eligibilities.txt,minimum_age,,text ,18 Years,,Converted all time values to numeric and standardized the unit to years.,,
eligibilities.txt,maximum_age,,text ,45Years,,Converted all time values to numeric and standardized the unit to years.,,
eligibilities.txt,healthy_volunteers,,binary,,t/f,No,,
eligibilities.txt,criteria,,text ,"Inclusion Criteria:~* A pregnant woman with a clinical or genetic diagnosis of TSC as determined by the 2021 Consensus Guidelines (1)~* A pregnant woman with a diagnosis of LAM~* A pregnant woman with a variant of uncertain significance in TSC 1 or TSC 2~* A pregnant woman who is pregnant and the fetus has a 50% chance of TSC as deemed by the PI or Sub-Is~* A pregnant woman whose fetus is found to have concern for TSC secondary to rhabdomyomas, tubers, or congenital subependymal giant cell astrocytoma.~* An infant born to an enrolled individual.~Exclusion Criteria:~* A pregnant woman without TSC who has used preimplantation genetic testing for TSC unless qualifies under inclusion criteria #4.~* Infants diagnosed with TSC whose birth mother was not enrolled.",,,,
studies.txt,brief_title,,text,Implications for Treatment of the Metabolic Syndrome,,,,
studies.txt,enrollment,,categorical,,"EARLY_PHASE1        
PHASE1 
PHASE1/PHASE2        
PHASE2 
PHASE2/PHASE3        
PHASE3        
PHASE4 ",No,,
,,,,,,,,
,,,,,,,,
studies.txt,enrollment,The number of participants in a clinical study. ,numeric ,,,,,
studies.txt,enrollment_type,"The ""estimated"" enrollment is the target number of participants that the researchers need for the study.",categorical,,"ACTUAL 
ESTIMATED ",NO,,
studies.txt,has_dmc,,,,,,,Data Monitoring Committee